Highlights Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
0.5945 ^USD	-4.10%		-11.27%	-34.85%

May. 07	Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 06	Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	May. 06	CI
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment	May. 06	RE
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine	May. 03	CI
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Gossamer Bio, Inc. to Present Results of TORREY FRI Sub- Study At the European Respiratory Society International Congress 2023	23-09-07	CI
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Gossamer Bio Inc. Announces FDA has Placed a Partial Clinical Hold on All Trials of GB5121 in Response to Serious Adverse Events	23-04-03	CI
GOSSAMER BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-17	AQ
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-17	CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-17	CI
Gossamer Bio, Inc. Announces Seralutinib Meets Primary Endpoint in Phase 2 Torrey Study in PAH	22-12-06	CI
GOSSAMER BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	22-11-03	AQ
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
GOSSAMER BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	22-08-09	AQ
Gossamer Bio Q2 Loss Narrows	22-08-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Highlights

Filters